FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Medical Devices

Let FDA Set AI Postmarket Standards: Califf

FDA commissioner Robert Califf asks Congress to give the agency the authority to set standards for postmarket evaluation of artificial intelligence in...

latest-news-card-1
Medical Devices

Multiple Adept Medical Violations Cited

FDA warns Auckland, New Zealand-based Adept Medical about Quality System and other violations in its production of ventilation tubes.

latest-news-card-1
Human Drugs

CGMP Violations at Italys Eurosirel

FDA warns Milan, Italy-based Eurosirel about CGMP violations in its production of finished drugs.

latest-news-card-1
Human Drugs

Oncologic Drugs Ovarian Toxicity Guidance

FDA publishes a draft guidance with recommendations to oncologic drug sponsors about measuring ovarian toxicity in relevant clinical trials.

latest-news-card-1
FDA General

Court Tosses Attorneys Privacy Suit Against FDA

The DC federal court agrees with FDA that a suit against the agency over identifying an attorney in a regulated company on a form FDA-483 should be di...

latest-news-card-1
Human Drugs

Satsuma Pharma NDA Resubmission for Migraine Drug

FDA accepts for review a Satsuma Pharmaceuticals NDA resubmission for STS101 (dihydroergotamine nasal powder) for the acute treatment of migraine with...

latest-news-card-1
Human Drugs

Axsome to File NDA on Narcolepsy Drug

Based on just-reported Phase 3 trial data, Axsome Therapeutics says it will submit an NDA for on AXS-12 (reboxetine) and its use in treating narcoleps...

latest-news-card-1
Human Drugs

Follow-up Testing for Ames-Positive Drugs: Guide

FDA posts a draft guidance entitled Recommended Follow-Up Testing for an Ames-Positive Drug (Active Ingredient) or Metabolite To Support First-in-Huma...

latest-news-card-1
Human Drugs

6 Observations on Regeneron FDA-483

FDA releases the form FDA-483 with six observations from an inspection at Limerick, Ireland-based Regeneron Ireland Designated Activity Company.

latest-news-card-1
Human Drugs

Alnylam Files sNDA for Vutrisiran

FDA accepts for review an Alnylam Pharmaceuticals supplemental NDA for vutrisiran, an investigational RNAi therapeutic in development for treating tra...